Using a digital tool to assess disease severity remotely is feasible for people with amyotrophic lateral sclerosis (ALS) and…
Articles by Margarida Maia, PhD
Stem cells engineered to mature into nerve-supporting cells that produce GDNF — a key factor for motor neuron survival —…
People with amyotrophic lateral sclerosis (ALS) have significantly higher blood levels of lead, a toxic heavy metal, than those…
Pasithea Therapeutics has gained access to AU$1 million (about $694,000) to further its research into anti-integrin antibodies as potential…
PandaOmics, an artificial intelligence (AI) platform that looks at vast amounts of data to find “druggable” molecules, has identified…
Corestem is still enrolling participants in its Phase 3 clinical trial of NeuroNata-R (lenzumestrocel), a stem cell therapy…
The U.S. Food and Drug Administration (FDA) has published on its website a five-year action plan meant to help advance…
NeuroSense Therapeutics’ combination therapy PrimeC led to a significant decline in certain biomarkers of amyotrophic lateral sclerosis (ALS) when…
A Phase 2b clinical trial evaluating NeuroSense Therapeutics’ experimental combination therapy PrimeC in people with amyotrophic lateral sclerosis (ALS)…
The Barrow Neurological Institute in Phoenix, Arizona, is calling on people with amyotrophic lateral sclerosis (ALS) and their…